SCHEMBL3269014

SCHEMBL3269014

COc1cc(C=O)c2ccccc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.55
MCL1 Q07820 1/20 0.50
CDC25B P30305 3/20 0.48
CYP1A2 P05177 3/20 0.47
CYP2A6 P11509 1/20 0.47
CASP3 P42574 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
ALDH1A1 P00352 5/20 0.45
CYP2C19 P33261 2/20 0.45
NQO2 P16083 1/20 0.45
LMNA P02545 1/20 0.45
CYP2C9 P11712 1/20 0.45
TRIM24 O15164 1/20 0.43
TYR P14679 1/20 0.43
TRIM33 Q9UPN9 1/20 0.43
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
HPGD P15428 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5252231 0.84 CYP1A2 (0.48) ERN1CDC25BCYP1A2CYP2A6CASP3
SCHEMBL15496951 0.82 CYP1A2 (0.47) ERN1CDC25BCYP1A2CYP2A6CASP3
SCHEMBL31618272 0.81 CYP1A2 (0.46) ERN1CDC25BCYP1A2CYP2A6CASP3
SCHEMBL29889957 0.81 SIRT2 (0.57) ERN1CYP1A2CYP2A6ALDH1A1CYP2C19
SCHEMBL13886669 0.81 KMT2A (0.49) ERN1MCL1CYP1A2ALDH1A1CYP2C19
SCHEMBL5383981 0.81 SIRT2 (0.57) ERN1CYP1A2CYP2A6ALDH1A1CYP2C19
SCHEMBL3267487 0.80 ERN1 (0.47) ERN1MCL1ALDH1A1LMNAKDM4E
SCHEMBL10971515 0.78 ERN1 (0.51) ERN1MCL1CYP1A2CYP2A6ALDH1A1
SCHEMBL20563413 0.78 RXRA (0.60) MCL1CDC25BCYP1A2ALDH1A1CYP2C19
SCHEMBL20563415 0.78 RXRA (0.60) MCL1CDC25BCYP1A2ALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3743061-A1 CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS Pascal Biosciences Inc. (CA) 2020-12-02 EP claimed
WO-2019144126-A1 CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS PASCAL BIOSCIENCES INC. (CA) 2019-07-25 WO claimed
CN-1681470-A Agent for dyeing keratinous fibres HENKEL KGAA (DE) 2005-10-12 CN claimed
WO-2025118034-A1 COMPOUNDS ACTIVE AT THE SEROTONERGIC 5-HT2A RECEPTOR Psylo Pty Ltd (AU) 2025-06-12 WO disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 EP disclosed
US-11446298-B2 Pyrimidine derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2022-09-20 US disclosed
EP-3625223-B1 PYRIMIDINE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2021-08-11 EP disclosed
EP-3743061-A1 CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS Pascal Biosciences Inc. (CA) 2020-12-02 EP disclosed
US-20200108068-A1 PYRIMIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2020-04-09 US disclosed
EP-3625223-A1 PYRIMIDINE DERIVATIVES Idorsia Pharmaceuticals Ltd (CH) 2020-03-25 EP disclosed
WO-2019144126-A1 CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS PASCAL BIOSCIENCES INC. (CA) 2019-07-25 WO disclosed
WO-2018210992-A1 PYRIMIDINE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2018-11-22 WO disclosed
EP-1914229-B1 NOVEL CERCOSPORAMIDE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-06-16 EP disclosed
US-20090036492-A1 Novel Cercosporamide Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-02-05 US disclosed
EP-1914229-A1 NOVEL CERCOSPORAMIDE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2008-04-23 EP disclosed
US-4384930-A Electroplating baths, additives therefor and methods for the electrodeposition of metals MCGEAN-ROHCO, INC. (US) 1983-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036492-A1 Novel Cercosporamide Derivative GPR119, CBR3, SLC5A2 ERN1 337/4885MCL1 3227/4885CDC25B 1404/4885
US-11446298-B2 Pyrimidine derivatives PTGER1, PTGER4, PTGER2 ERN1 647/4885MCL1 2227/4885CDC25B 1473/4885
US-20200108068-A1 PYRIMIDINE DERIVATIVES PTGER1, PTGER4, PTGER2 ERN1 647/4885MCL1 2227/4885CDC25B 1473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.